Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Good morning, and welcome to the Ocular Therapeutix SOL-1 Topline Data Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded, and a replay will be made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results